Why is xcopri so expensive

Overview

Xcopri (cenobamate) is an anticonvulsant medication developed specifically for adults with focal-onset seizures, a common form of epilepsy affecting approximately 60% of the 3.4 million Americans with epilepsy. Approved by the U.S. Food and Drug Administration (FDA) on November 21, 2019, it represents one of the newer treatment options for patients who haven't responded adequately to other medications. The drug was developed by SK Life Science, a subsidiary of South Korea's SK Group, and marked their first FDA-approved neurological drug. Clinical development began in 2012, with pivotal Phase 3 trials completed in 2018 showing significant seizure reduction—55% median reduction in seizure frequency compared to placebo. The medication entered the U.S. market in early 2020 through a restricted distribution system requiring prescribers to enroll in the Xcopri REMS (Risk Evaluation and Mitigation Strategy) program due to potential serious side effects including drug reaction with eosinophilia and systemic symptoms (DRESS).

How It Works

Xcopri operates through a dual mechanism of action that distinguishes it from many other antiepileptic drugs. Primarily, it enhances GABAergic inhibition by positively modulating GABA-A receptors, specifically targeting subtypes containing β2 and β3 subunits. This action increases chloride ion flow into neurons, making them less excitable and reducing seizure activity. Additionally, cenobamate inhibits voltage-gated sodium channels in a use-dependent manner, preferentially binding to channels in their inactivated state during high-frequency neuronal firing characteristic of seizures. This dual approach—combining GABA enhancement with sodium channel blockade—provides broader seizure control than single-mechanism drugs. The medication is administered orally once daily, starting at 12.5 mg and titrating up to a maximum of 400 mg based on tolerability and response. Its pharmacokinetics show high bioavailability (88%) and a half-life of approximately 50-60 hours, allowing for stable blood levels with once-daily dosing. Metabolism occurs primarily through glucuronidation and oxidation via CYP2E1 and CYP2A6 enzymes.

Why It Matters

Xcopri's significance lies in addressing treatment-resistant focal seizures, where approximately one-third of epilepsy patients fail to achieve adequate control with existing medications. In clinical trials, 21% of patients achieved seizure freedom during the maintenance phase—a notable result for this difficult-to-treat population. The high cost, while burdensome, reflects the substantial investment in developing effective treatments for neurological conditions that historically received limited research funding. For patients, access challenges due to pricing highlight broader healthcare system issues, including insurance barriers and specialty pharmacy requirements. The drug's REMS program, while ensuring safe use, adds administrative complexity that can delay treatment initiation. As healthcare systems grapple with balancing innovation costs against patient affordability, Xcopri serves as a case study in neurology drug development economics, with implications for future epilepsy treatments and pricing models for specialized medications.